Evidence map›Paper›PMID 39221824›Full record

Trial reportCirculation. Cardiovascular imaging2024

Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial.

Milind Y Desai, Yuichiro Okushi, Andrew Gaballa, Qiuqing Wang, Jeffrey B Geske, Anjali T Owens, Sara Saberi, Andrew Wang, Paul C Cremer, Mark Sherrid and 9 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Circulation. Cardiovascular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04349072 (A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy), which is not on this map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04349072 phase3completednot on this map

A Randomized, Double-blind, Placebo-controlled Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy

TypeinterventionalSponsorBristol-Myers SquibbRan2020 to 2024Enrolled112ConditionsHOCM, Hypertrophic Obstructive CardiomyopathyArmsMavacamten, Placebo
3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Observational
  14. Cardiac myosin inhibitors in hypertrophic cardiomyopathy.Journal of cardiovascular imaging · 2025
    Review
  15. Review
  16. Review
  17. Observational
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Milind Y DesaiHypertrophic Cardiomyopathy Center (M.Y.D., Y.O., A.G., Z.B.P.), Heart Vascular and Thoracic Institute, Cleveland Clinic, OH.ORCID 0000-0003-0010-9797
Yuichiro OkushiHypertrophic Cardiomyopathy Center (M.Y.D., Y.O., A.G., Z.B.P.), Heart Vascular and Thoracic Institute, Cleveland Clinic, OH.ORCID 0009-0004-8534-6760
Andrew GaballaHypertrophic Cardiomyopathy Center (M.Y.D., Y.O., A.G., Z.B.P.), Heart Vascular and Thoracic Institute, Cleveland Clinic, OH.ORCID 0009-0008-8619-3400
Qiuqing WangCleveland Clinic Coordinating Center for Clinical Research (M.Y.D., Q.W., P.C.C., S.E.N., Z.B.P.), Heart Vascular and Thoracic Institute, Cleveland Clinic, OH.
Jeffrey B GeskeDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN (J.B.G.).ORCID 0000-0003-1671-4262
Anjali T OwensDivision of Cardiology, University of Pennsylvania, Philadelphia (A.T.O.).ORCID 0000-0002-9669-8495
Sara SaberiDepartment of Internal Medicine, University of Michigan, Ann Arbor (S.S.).ORCID 0000-0003-4473-6725
Andrew WangDepartment of Cardiology, Duke University, Durham, NC (A.W.).ORCID 0000-0001-8729-0933
Paul C CremerCleveland Clinic Coordinating Center for Clinical Research (M.Y.D., Q.W., P.C.C., S.E.N., Z.B.P.), Heart Vascular and Thoracic Institute, Cleveland Clinic, OH.ORCID 0000-0002-0794-3306
Mark SherridDepartment of Cardiology, New York University, NY (M.S.).ORCID 0000-0003-4972-7780
Neal K LakdawalaDivision of Cardiology, Mass General Brigham, Boston, MA (N.K.L., A.T.-R.).ORCID 0000-0001-6458-5421
Albree Tower-RaderDivision of Cardiology, Mass General Brigham, Boston, MA (N.K.L., A.T.-R.).ORCID 0000-0001-7242-0774
David FerminDepartment of Cardiology, Corewell Health, Grand Rapids, MI (D.F.).
Srihari S NaiduDepartment of Cardiology, Westchester Medical Center, Valhalla, NY (S.S.N.).ORCID 0000-0003-4073-5143
Kathy L LamplBristol Myers Squibb, Princeton, NJ (K.L.L., A.J.S.).
Amy J SehnertBristol Myers Squibb, Princeton, NJ (K.L.L., A.J.S.).ORCID 0000-0003-1912-1710
Steven E NissenHypertrophic Cardiomyopathy Center (M.Y.D., Y.O., A.G., Z.B.P.), Heart Vascular and Thoracic Institute, Cleveland Clinic, OH.ORCID 0000-0002-7231-6464
Zoran B PopovicHypertrophic Cardiomyopathy Center (M.Y.D., Y.O., A.G., Z.B.P.), Heart Vascular and Thoracic Institute, Cleveland Clinic, OH.ORCID 0000-0001-5692-2299
VALOR-HCM Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain.

methodsVALOR-HCM included 112 patients with symptomatic obstructive hypertrophic cardiomyopathy (mean, 60 years; 51% male; LV ejection fraction, 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo (n=52) transitioned to mavacamten from weeks 16 to 56 (40-week exposure). LV-GLS and RV-GLS assessment was performed using a vendor-neutral software. Non-foreshortened apical (4-, 3-, and 2-chamber) views were used to obtain peak LV-GLS. RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable.

resultsAt baseline, the mean LV-GLS, RV 4-chamber, and free wall strain values were -14.7%, -22.2%, and -16.8%, respectively (all worse than reported normal means). In the total study sample, LV-GLS significantly improved from baseline to week 56 (

conclusionsIn VALOR-HCM, treatment with mavacamten improved LV-GLS from baseline through week 56 (with no significant worsening of LV-GLS in patients with a reduction in LV ejection fraction ≤50%), suggesting a favorable long-term impact on regional LV systolic function. Additionally, there was no detrimental impact on RV systolic function. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04349072.

Indexed as

Cardiomyopathy, HypertrophicStroke VolumeVentricular Function, LeftVentricular Function, RightAgedBenzylaminesDouble-Blind MethodFemaleGlycineHumansMaleMiddle AgedRecovery of FunctionTime FactorsTreatment OutcomeUracilBenzylaminesGlycineMYK-461Uracilcardiomyopathy, hypertrophic obstructiveglobal longitudinal strainMavacamten

Identifiers

PMID39221824
PMCPMC11410149

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.